The company is focused on addressing the lack of effective treatment options for endometriosis, a painful disease that affects over 10% of women worldwide and is the leading cause of infertility and disability among women in their reproductive years. By developing revolutionary molecules that can target endometriosis cells and discovering a new biochemical pathway that triggers the disease, EndoCyclic Therapeutics aims to provide a solution for the millions of women suffering from endometriosis. Founded in 2017 and based in Irvine, California, the company brings together a team of world-class physicians, scientists, government officials, and pharma/biotech professionals to raise awareness about this important women's health issue and offer a path to remission from the disease.